International Workshop on CLL
Pirtobrutinib to be Compared with Ibrutinib in CLL/SLL Ongoing BRUIN CLL-314 Trial
October 13th 2023The phase 3 BRUIN CLL-314 trial evaluating the selective noncovalent BTK inhibitor pirtobrutinib vs the potent covalent BTK inhibitor ibrutinib is currently enrolling patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who previously received treatment with non-BTK inhibitor therapy.
Dr Coombs on Switching to Treatment With a BCL-2 Inhibitor Vs a Covalent BTK Inhibitor in CLL/SLL
October 10th 2023Catherine C. Coombs, MD, discusses the feasibility of switching from treatment with a covalent BTK inhibitor to a BCL-2 inhibitor vs a different covalent BTK inhibitor in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma treated in a real-world setting.
Acalabrutinib Is Associated With Low Frequency of Cardiac Events Across 3 Randomized Trials in CLL
October 9th 2023Administration of acalabrutinib to patients with chronic lymphocytic leukemia with or without cardiovascular disorders at baseline results in a numerically decreased incidence of overall treatment-related cardiac toxicities and a comparable safety profile vs comparator CLL therapies such as ibrutinib.
Venetoclax Elicits Responses in B-Cell Receptor–Pretreated CLL Regardless of Mutation Status
October 9th 2023Treatment with single-agent venetoclax led to prolonged disease response in patients with chronic lymphocytic leukemia who had relapsed or become refractory to prior B-cell receptor inhibitors including ibrutinib and idelalisib, according to findings from a phase 2 study.
Continued Maintenance With Obinutuzumab Plus Acalabrutinib/Venetoclax Boosts uMRD Rate in R/R CLL
The undetectable minimal residual disease ate achieved with bendamustine followed by obinutuzumab, acalabrutinib, and venetoclax increased as the regimen was continued as maintenance treatment in patients with relapsed or refractory chronic lymphocytic leukemia.
Epcoritamab Monotherapy Demonstrates High Response Rates in High-Risk Relapsed/Refractory CLL
October 9th 2023Treatment with subcutaneous epcoritamab-bysp elicited rapid and durable responses, including an encouraging complete response rate, and manageable safety in high-risk patients with relapsed/refractory chronic lymphocytic leukemia.
Patients with chronic lymphoctyic leukemia treated with pirtobrutinib monotherapy experienced comparable objective response rates regardless of acquired BTK mutation and a decrease or clearance of BTK cysteine 481 clones despite the emergence of non-C481 clones or other less common mutations during or near the time of progression.
Venetoclax and Rituximab Combination Maintains Survival Benefit in Relapsed/Refractory CLL
Patients with relapsed/refractory chronic lymphocytic leukemia achieved sustained progression-free survival and overall survival benefit after treatment with fixed-duration venetoclax plus rituximab vs bendamustine plus rituximab, according to data from the phase 3 MURANO trial.
Dr Woyach on the Prevalence of Mutations in Previously Treated Patients With CLL
October 8th 2023Jennifer A Woyach, MD, discusses the prevalence of recurrent genomic alterations in apoptotic machinery in patients with previously treated chronic lymphocytic leukemia who were refractory to B-cell receptor pathway inhibitors.
Retrospective Analysis Sheds Light on Mutations Linked With BTK Inhibitor Resistance in CLL
October 8th 2023Patients with chronic lymphocytic leukemia who experience disease progression during treatment with either covalent or noncovalent BTK inhibitors displayed a higher frequency of BTK mutations in L528W as well as RAS/RAF/MAPK pathway alterations, indicating that these alterations may play a role in the development of BTK inhibitor resistance.
Dr Shadman on Zanubrutinib in CLL/SLL Intolerant to Prior BTK Inhibitors
October 8th 2023Mazyar Shadman, MD, MPH, discusses preliminary long-term findings from the evaluation of zanubrutinib in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were intolerant to ibrutinib and/or acalabrutinib.
MRD Could Guide Venetoclax/Ibrutinib Duration in Previously Untreated, Intermediate-Risk CLL
The duration of treatment with the combination of venetoclax and ibrutinib could be guided by both toxicities and minimal residual disease kinetics in previously untreated patients with intermediate-risk chronic lymphocytic leukemia, according to interim results from the phase 2 ERADIC trial.
Mutational Status Is Associated With Time to First Treatment in Newly Diagnosed CLL
October 21st 2021The presence of at least 1 mutation captured by next-generation sequencing was associated with a shorter time to first treatment among patients with newly diagnosed chronic lymphocytic leukemia, particularly those with mutations in POT1, ATM, FBXW7, and MYD88 genes.
Acalabrutinib, Alone or With Obinutuzumab, Improves Quality-Adjusted Survival in Frontline CLL
Treatment with acalabrutinib as monotherapy or in combination with obinutuzumab improved quality-adjusted survival compared with chlorambucil plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia.
U2 Plus Pembrolizumab Shows Continued Efficacy at 5 Years in CLL and Richter’s Transformation
September 20th 2021The triplet combination of umbralisib, ublituximab, and pembrolizumab demonstrated durable responses with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation.
Liso-cel Plus Ibrutinib Demonstrates Tolerable Safety Profile in Relapsed/Refractory CLL/SLL
September 19th 2021Lisocabtagene maraleucel in combination with ibrutinib was associated with manageable safety for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to updated data from the phase 1 TRANSCEND-CLL-004 trial.
